JPRN-UMIN000012018已完成未知
Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer. - Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Past history of severe hypersensitivity. 2) History of eribulin use during 6 months prior to consent. 3) Active multiple primary malignancy. 4) Patients with uncontrolled infection. 5) Patient with disease requiring emergent intervention. 6) Patients with progressive brain metastasis requiring treatment during 6 months prior to consent. 7) Patients with severe complications. 8) Pregnant or breastfeeding. 9) Patients who deny contraception during this study. 10) Any other cases that the attending doctor judges not appropriate to enroll to this study.
研究者
相似试验
已完成
2 期
Combination therapy of Eribulin with Trastuzumab for HER2 positive metastatic breast cancer.HER2 positive metastatic breast cancerJPRN-UMIN000009296Setouchi Breast Project30
已完成
2 期
Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)HER2 positive metastatic breast cancerJPRN-UMIN000010761Kurume University School of Medicine Department of Surgery30
尚未招募
2 期
Phase II study of eribulin with trasutuzumab for pretreated locally advanced / metastatic HER2-positive breast cancerlocally advanced / metastatic HER2-positive breast cancerJPRN-UMIN000012350agoya University50
尚未招募
2 期
Phase II trial with eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancerBreast cancerJPRN-UMIN000010844The University of Tokushima graduate school30
已完成
2 期
A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerFirst or second line therapy for advanced or recurrent HER2-positive breast cancer patients who have received taxane and trasutuzumab as adjuvant or recurrent therapy.JPRN-UMIN000012232JBCRG(Japan Breast Cancer Research Group)46